Strs Ohio bought a new position in shares of Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 15,900 shares of the company’s stock, valued at approximately $32,000.
Several other hedge funds have also recently bought and sold shares of PEAR. Vanguard Group Inc. lifted its stake in Pear Therapeutics by 67.9% during the 1st quarter. Vanguard Group Inc. now owns 1,045,443 shares of the company’s stock worth $5,280,000 after acquiring an additional 422,804 shares in the last quarter. BlackRock Inc. acquired a new position in Pear Therapeutics during the 1st quarter worth about $2,102,000. State Street Corp lifted its stake in Pear Therapeutics by 296.4% during the 2nd quarter. State Street Corp now owns 312,028 shares of the company’s stock worth $481,000 after acquiring an additional 233,313 shares in the last quarter. Millennium Management LLC lifted its stake in Pear Therapeutics by 574.1% during the 2nd quarter. Millennium Management LLC now owns 248,399 shares of the company’s stock worth $383,000 after acquiring an additional 211,551 shares in the last quarter. Finally, Acropolis Investment Management LLC acquired a new position in Pear Therapeutics during the 3rd quarter worth about $336,000. Institutional investors and hedge funds own 71.17% of the company’s stock.
Analysts Set New Price Targets
PEAR has been the topic of several research reports. Citigroup decreased their target price on Pear Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, November 16th. Credit Suisse Group cut their price target on Pear Therapeutics from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, November 15th. Finally, Chardan Capital cut their price target on Pear Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Pear Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.
Pear Therapeutics Stock Performance
Pear Therapeutics (NASDAQ:PEAR – Get Rating) last released its quarterly earnings data on Monday, November 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.01). Pear Therapeutics had a negative net margin of 265.26% and a negative return on equity of 185.33%. The business had revenue of $4.08 million during the quarter. As a group, analysts predict that Pear Therapeutics, Inc. will post -0.85 earnings per share for the current fiscal year.
In other news, major shareholder 5Am Partners Iv, Llc sold 10,578 shares of the stock in a transaction dated Wednesday, November 2nd. The stock was sold at an average price of $2.72, for a total value of $28,772.16. Following the transaction, the insider now owns 539,066 shares in the company, valued at approximately $1,466,259.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 94,250 shares of company stock worth $273,547. 30.70% of the stock is currently owned by insiders.
Pear Therapeutics Company Profile
Pear Therapeutics, Inc, a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia.
- Get a free copy of the StockNews.com research report on Pear Therapeutics (PEAR)
- CVS Health is Growing into an Integrated Healthcare Organization
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.